Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China

Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China

ObjectivesThe ETER701 trial demonstrated that benmelstobart combined with anlotinib and etoposide-carboplatin (EC) significantly extends survival in patients with extensive-stage small cell lung cancer (ES-SCLC), setting a new record for median overall survival. In contrast, anlotinib plus EC only s...

Full description

Saved in:
Bibliographic Details
Main Authors: Caicong You, Jiahao Zhang, Jianying Lei, Wu Fu, Bin Zheng, Maobai Liu, Na Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Oncology
Subjects:
cost-effectiveness
benmelstobart
anlotinib
extensive-stage small-cell lung
scenario analysis
R software
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1484650/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1484650/full

Similar Items